Payment overview · 2025
General Payments
$14.83
1 reported records · 1 companies
Healthcare provider profile · identity verified
Paul Peter Povanda, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · ELMIRA, NY · NPI 1164525325
Verified facts
What the public records show
CMS Open Payments records show Paul Peter Povanda, D.O. received $14.83 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.83 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.83 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 840 | 183 |
| Omeprazole | Omeprazole | 514 | 92 |
| Lisinopril | Lisinopril | 509 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 441 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 383 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 74 |
| Gabapentin | Gabapentin | 334 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 55 |
| Potassium Chloride | Potassium Chloride | 280 | 51 |
| Metformin Hcl | Metformin Hcl | 278 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 274 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 256 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 72 |
| Losartan Potassium | Losartan Potassium | 237 | 51 |
| Simvastatin | Simvastatin | 237 | 53 |
| Furosemide | Furosemide | 199 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 195 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 38 |
| Montelukast Sodium | Montelukast Sodium | 181 | 33 |
| Eliquis | Apixaban | 177 | 34 |
| Alprazolam | Alprazolam | 169 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 151 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 146 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 33 |
| Glipizide | Glipizide | 133 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 31 |
| Ibuprofen | Ibuprofen | 121 | 35 |
| Sertraline Hcl | Sertraline Hcl | 112 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 22 |
| Tramadol Hcl | Tramadol Hcl | 103 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 100 | 18 |
| Trazodone Hcl | Trazodone Hcl | 94 | 17 |
| Buspirone Hcl | Buspirone Hcl | 90 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 87 | 11 |
| Jardiance | Empagliflozin | 84 | 15 |
| Pregabalin | Pregabalin | 80 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 16 |
| Januvia | Sitagliptin Phosphate | 77 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 21 |
| Allopurinol | Allopurinol | 76 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 16 |
| Levetiracetam | Levetiracetam | 73 | 11 |
| Meloxicam | Meloxicam | 73 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 71 | 13 |
| Ramipril | Ramipril | 71 | 20 |
| Valsartan | Valsartan | 71 | suppressed |
| Atenolol | Atenolol | 70 | 14 |
| Alendronate Sodium | Alendronate Sodium | 67 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 66 | 11 |
| Xarelto | Rivaroxaban | 64 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 14 |
| Carvedilol | Carvedilol | 62 | 11 |
| Celecoxib | Celecoxib | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | suppressed |
| Ezetimibe | Ezetimibe | 60 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | suppressed |
| Aripiprazole | Aripiprazole | 54 | suppressed |
| Clonazepam | Clonazepam | 54 | 14 |
| Lorazepam | Lorazepam | 53 | 13 |
| Nystatin | Nystatin | 53 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 52 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Prednisone | Prednisone | 50 | 24 |
| Cefuroxime | Cefuroxime Axetil | 49 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Sucralfate | Sucralfate | 48 | suppressed |
| Lansoprazole | Lansoprazole | 46 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 11 |
| Donepezil Hcl | Donepezil Hcl | 44 | 11 |
| Spironolactone | Spironolactone | 44 | 11 |
| Cephalexin | Cephalexin | 41 | 25 |
| Torsemide | Torsemide | 41 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Ranolazine Er | Ranolazine | 40 | suppressed |
| Vascepa | Icosapent Ethyl | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Famotidine | Famotidine | 37 | 13 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 21 |
| Azithromycin | Azithromycin | 24 | 21 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 12 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Imipramine Hcl | Imipramine Hcl | 21 | suppressed |
| Niacin Er | Niacin | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.83 · 1 records | ABBVIE INC. | CREON, LINZESS | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error